Enya Hui Wen Ong

Enya Hui Wen Ong

Auto-generated profile, based on publicly available information

Enya Hui Wen Ong

Division of Medical Sciences, National Cancer Centre Singapore, 30 Hospital Blvd, 168583, Singapore

Research Focus & Metrics

Academic Career Length

6Years (2021-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
5 December 2023 in Oral Oncology
Verified
Journal Article
Open access
JNJialing Neo
Jialing Neo
PYPui Lam Yip
Pui Lam Yip
EOEnya H.W. Ong
Enya H.W. Ong
JMJingjing Miao
Jingjing Miao
WCWen Min Chow
Wen Min Chow
MCMelvin LK Chua
Melvin LK Chua
To characterize longitudinal changes in Epstein-Barr virus (EBV) DNA post-radiotherapy in nasopharyngeal carcinoma (NPC) patients, and investigate whether an early (0-2 weeks) or delayed (8-12 weeks) EBV DNA result better predicts for disease-free survival (DFS). Histologically-confirmed NPC patients with ≥1 EBV DNA test quantified using the harmonized BamHI-W polymerase chain reaction-based assay at 0-2 and 8-12 weeks post-radiotherapy were included. We identified 302 patients with EBV DNA measured at 0-2 weeks post-radiotherapy; of which, 110 (36.4 %) underwent a repeat test at 8-12 weeks post-treatment. Patients harboring a detectable EBV DNA at 0-2 weeks experienced an inferior DFS (adjusted HR1-264 copies 1.72 [95 %CI: 1.05-2.83], P = 0.031; AHR≥265 copies 4.39 [95 %CI: 1.68-11.44], P = 0.002 relative to 0 copies/mL). At 8-12 weeks, we observed substantial shifts in EBV DNA readings from 0 to 2 weeks; 76/110 (69.1 %) and 34/110 (30.9 %) patients at 0-2 weeks versus 90/110 (81.8 %) and 20/110 (18.2 %) at 8-12 weeks recorded undetectable and detectable EBV DNA, respectively. Positive EBV DNA at 8-12 weeks was strongly associated with relapse (73.3 % [11/15] for 1-264; 80.0 % [4/5] for ≥265 subgroups had relapses versus 15.6 % [14/90] for 0 copies/mL). Area under receiver operating curve values for 2-year relapse rates were 0.817 (95 %CI: 0.725-0.909) for stage + EBV DNA8-12w versus 0.654 (95 %CI: 0.542-0.765) for stage + EBV DNA0-2w. CONCLUSION: EBV DNA is dynamic post-radiotherapy, and delayed EBV DNA testing better enriched for higher-risk NPC patients. This implicates trials investigating adjuvant chemotherapy intensification based on early EBV DNA testing.

1 April 2025 in European Journal of Cancer
Verified
Journal Article
Open access
JNJialing Neo
Jialing Neo
EOEnya H.W. Ong
Enya H.W. Ong
XZXin Zhang
Xin Zhang
WCWen Min Chow
Wen Min Chow
JWJoseph T.S. Wee
Joseph T.S. Wee
MCMelvin LK Chua
Melvin LK Chua
Plasma Epstein-Barr virus (EBV) DNA is an archetypal biomarker for endemic nasopharyngeal carcinoma (NPC) employed for disease surveillance and early detection of recurrences. However, its accuracy is unknown. We utilised a single institution dataset with homogeneous surveillance procedures and routine EBV DNA testing using a harmonised assay to investigate its accuracy for recurrence detection. We utilised a cohort of patients with histologically-confirmed, non-metastatic NPC treated from February, 2017 to July, 2023. All patients had ≥ 1 EBV DNA test using the harmonised BamHI-W polymerase chain reaction-based assay within 3 years post-radiotherapy (RT). We analysed the negative (NPV) and positive predictive values (PPV) for recurrence over a 1-year window (at 3-monthly intervals - windows 1-4) for each test performed. Recurrence was ascertained by radiological imaging and/or histopathological confirmation. Of 1746 EBV DNA readings from 393 patients diagnosed between January, 2017 to May, 2023, 1385 (79.3 %), 294 (16.8 %), and 67 (3.9 %) were recorded as negative, low (< 500 copies/mL), and high EBV DNA (≥ 500 copies/mL), respectively. NPVs of the assay were high (range: 97.6-99.3 %). PPVs were modest, highest at window 1 (range: 26.3-34.3 %) compared with the other 3 windows (range: 2.6-10.5 %). Sensitivity analyses revealed that PPVs were threshold-dependent; 71.4-100 % at window 1 for ≥ 500 copies/mL versus 16.9-23.1 % for < 500 copies/mL, which corresponded to median time of recurrence onset (0.8 vs 4.8 months, respectively). Negative EBV DNA test results have high NPVs, suggesting that patients may be routinely surveyed, while a positive result of ≥ 500 copies/mL indicates high recurrence risk.

20 February 2022 in Journal of Clinical Oncology
Verified
Journal Article
Closed access
ALAdelene Sim Yen Ling
Adelene Sim Yen Ling
AHAlexander K. Hakansson
Alexander K. Hakansson
EOEnya Hui Wen Ong
Enya Hui Wen Ong
ALAmanda S.Y. Lau
Amanda S.Y. Lau
KLKar Perng Low
Kar Perng Low
MCMelvin LK Chua
Melvin LK Chua
273 Background: The Decipher 22-gene genomic classifier (GC) has been shown to predict for metastasis and survival in predominantly Caucasian and African-American men from Western cohorts. There is however little data on the clinical utility of GC in Asian prostate cancer (PCa). We investigated if GC prognosticates for metastasis-free survival (MFS) in an Asian cohort of localized PCa. Additionally, we performed comparative genomic analyses between our Asian patients and non-Asian cases from a large Decipher GRID database (Veracyte, San Francisco, CA). Methods: We used a cohort of PCa patients who were treated at a single institution from East Asia between 2006 to 2021. Patients underwent active surveillance or radical prostatectomy (RadP) and/or radiotherapy (RT) +/- hormonal therapy (HT). The GC assay (Decipher Biosciences, CA) was performed on diagnostic biopsies, following central review of the Gleason’s grade (GG) and tumor cellularity by an expert GU pathologist. MFS was the primary endpoint for survival analysis. Comparative analyses of 273 gene-signatures were performed against the full and a propensity-score matched (PSM) cohort identified from the Decipher GRID database. Adjusted p-values from Wilcoxon tests were used to select from these signatures. Results: We profiled 126 unique patient tumors, comprising of 19 (15.1%) NCCN-defined low-/favorable intermediate-, 22 (17.5%) unfavorable intermediate-, 34 (27.0%) high-, and 51 (40.5%) very high-risk groups. 24 (19.0%) patients had RadP as primary treatment, 98 (77.8%) had RT +/- HT, while 4 (3.2%) underwent active surveillance or HT alone. Using the GC, 70 (55.6%), and 56 (44.4%) were stratified as low/intermediate- (≤0.6) and high-risk ( > 0.6), respectively. GC high-risk was significantly associated with an inferior MFS than GC low/intermediate-risk ( HR 5.22 [95% CI:1.08–25.3], P = 0.04). Comparison between our Asian and the full unmatched GRID cohort (N = 80,703) revealed a lower proportion of ERG+ PCa (14% vs 41%, P < 0.001) and a higher proportion of PAM50 basal subtypes (41% vs 30%, P < 0.001), as well as a lower T-cell exclusion (median 0.080 vs 0.097; P < 0.001) and angiogenesis (-0.37 vs -0.08; P < 0.001) signature scores. These trends were also observed when comparing with the PSM-subset (N = 630; 5:1 ratio for NCCN, GG, age at diagnosis, and assay quality score). Interestingly, both high angiogenesis and T-cell exclusion signatures were associated with a worse MFS ( HR not available due to no events for low angiogenesis, P = 0.0015 by log-rank test; HR 5.12 [1.03–26.5], P = 0.046, respectively). Conclusions: We validated the Decipher 22-gene GC for prognostication of MFS in a predominantly high-risk PCa cohort. We also identified several gene expression signatures that were significantly different between Asian PCa and other cohorts. These observations may have implications for customizing treatment recommendations to an Asian population.

1 September 2024 in Cancer Research Communications
Verified
Journal Article
Open access
PDF file
RHRoni Haas
Roni Haas
GFGavin Frame
Gavin Frame
SKShahbaz Khan
Shahbaz Khan
Beth NeilsenBeth Neilsen
Beth Neilsen
BHBoon Hao Hong
Boon Hao Hong
SLStanley K Liu
Stanley K Liu
Prostate cancer is frequently treated with radiotherapy. Unfortunately, aggressive radioresistant relapses can arise, and the molecular underpinnings of radioresistance are unknown. Modern clinical radiotherapy is evolving to deliver higher doses of radiation in fewer fractions (hypofractionation). We therefore analyzed genomic, transcriptomic, and proteomic data to characterize prostate cancer radioresistance in cells treated with both conventionally fractionated and hypofractionated radiotherapy. Independent of fractionation schedule, resistance to radiotherapy involved massive genomic instability and abrogation of DNA mismatch repair. Specific prostate cancer driver genes were modulated at the RNA and protein levels, with distinct protein subcellular responses to radiotherapy. Conventional fractionation led to a far more aggressive biomolecular response than hypofractionation. Testing preclinical candidates identified in cell lines, we revealed POLQ (DNA Polymerase Theta) as a radiosensitizer. POLQ-modulated radioresistance in model systems and was predictive of it in large patient cohorts. The molecular response to radiation is highly multimodal and sheds light on prostate cancer lethality. Significance: Radiation is standard of care in prostate cancer. Yet, we have little understanding of its failure. We demonstrate a new paradigm that radioresistance is fractionation specific and identified POLQ as a radioresistance modulator.

14 December 2021 in Asia-Pacific Journal of Clinical Oncology
Verified
Journal Article
Open access
PDF file
JTJanice S. H. Tan
Janice S. H. Tan
JTJonathan Y. H. Teh
Jonathan Y. H. Teh
LTLaura L. Y. Tan
Laura L. Y. Tan
STSheena X. F. Tan
Sheena X. F. Tan
YLYou Quan Li
You Quan Li
MCMelvin LK Chua
Melvin LK Chua
Aims: Ultra‐hypofractionated radiotherapy (UHF‐RT) is widely utilized in men with localized prostate cancer (PCa). There are limited data in Asian cohorts. We report the outcomes of a single‐arm, phase II trial of UHF‐RT from an Asian center.Methods: We recruited men with histologically confirmed, nonmetastatic localized PCa. UHF‐RT regimens were 36.25 Gy (Cohort A) and 37.5 Gy (Cohort B) delivered in five fractions every other day over 1.5–2.5 weeks. Primary endpoint was physician‐scored late genitourinary (GU) and gastrointestinal (GI) adverse events (AEs). Quality‐of‐life (QoL) was assessed by Expanded Prostate Cancer Index Composite (EPIC) at baseline, 1‐ and 2‐year post‐UHF‐RT.Results: Between March 2014 and August 2019, 105 men were recruited; four were subsequently excluded from analysis. Median age was 68.0 (Interquartile range (IQR): 63.8–73.0) years. 26 (24.8%) and 68 (64.8%) men had NCCN‐defined low‐and intermediate‐risk PCa, respectively. No late ≥G3 GU or GI toxicities were reported in both cohorts. Peak incidence of acute ≥G2 GU AEs at 14 days post‐UHF‐RT was 23.6% (17/72) and 24.0% (6/25) in Cohorts A and B, respectively; ≥G2 GI AEs were observed in 9.7% (7/72) and 36.0% (9/25), respectively. Late ≥G2 GU and GI AEs occurred in 4.7% and 3.1% of Cohort A patients, and 5.0% in Cohort B at 12 months, with no AEs at 24 months. EPIC scores changed minimally across all domains. At a median follow‐up of 44.9 months, we recorded one (1.3%) biochemical relapse by the Phoenix criteria (Cohort A).Conclusion: UHF‐RT is well tolerated in Asian men and can be a recommended fractionation schema for localized PCa.

28 May 2025 in Journal of the National Cancer Center
Verified
Journal Article
Open access
KTKae Jack Tay
Kae Jack Tay
BHBoon Hao Hong
Boon Hao Hong
EOEnya Hui Wen Ong
Enya Hui Wen Ong
KTKah Min Tan
Kah Min Tan
GPGianella Cabuhat Pacho
Gianella Cabuhat Pacho
MCMelvin Lee Kiang Chua
Melvin Lee Kiang Chua
Focal therapy (FT) is a potential treatment option for limited-volume clinically-significant prostate cancer (csPCa). However, despite rigorous selection, approximately 20% of patients experience early failure. We investigated the association of transcriptomic profiles and csPCa recurrence post-FT. 52 men from a phase II trial (NCT04138914) and a prospective observational cohort underwent focal cryotherapy for csPCa. Patients underwent multiparametric magnetic resonance imaging, and targeted and systematic-saturation biopsy before- and 1-year post-FT. Recurrence was defined as grade-group (GG) ≥2 cancer in the 1-year post-FT biopsy. Pre-treatment lesions were profiled using the Decipher genomic classifier (GC). GC scores, luminal-basal status, tumor microenvironment and cancer hallmark pathways were correlated with csPCa recurrence. Median PSA was 7.0 ng/dl; 37/52 (71.1%) men had GG2, 12/52 (23.1%) GG3, and 3/52 (5.8%) GG4 cancer. Recurrence was observed in 9/52 (17.3%) men. Median GC score was higher in patients with recurrence (0.60 vs 0.38, P = 0.014) and remained significantly associated with recurrence after adjustment for GG (adjusted OR: 1.37 [95% CI: 1.01-1.93], P = 0.04). Luminal-proliferative tumors based on the prostate cancer-specific subtyping classifier (PSC) had more csPCa recurrence compared with luminal-differentiated (LD) and basal subtypes (30.4% vs 0% [LD] vs 15.4% [basal-neuroendocrine] and 14.3% [basal-immune], P = 0.027). Higher expression of DNA repair pathway was also associated with recurrence (OR: 2.12 [95% CI: 1.09-4.57], P = 0.025). Higher GC score is associated with risk of csPCa recurrence post-FT. Patients with GC low-risk and PSC-LD csPCa may represent the ideal subgroup for FT. Prospective validation in a large cohort is warranted.